• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.MVA-B 对宿主基因的选择性诱导,一种针对 HIV/AIDS 的候选疫苗。
J Virol. 2010 Aug;84(16):8141-52. doi: 10.1128/JVI.00749-10. Epub 2010 Jun 9.
2
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.系统分析 MVA-C 诱导的免疫反应揭示了其作为针对 C 型 HIV/AIDS 的候选疫苗的重要性。
PLoS One. 2012;7(4):e35485. doi: 10.1371/journal.pone.0035485. Epub 2012 Apr 19.
3
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.一种基于改良安卡拉痘苗病毒(MVA-B)的 HIV-1 疫苗在单独或联合一种药物重新激活潜伏 HIV-1 的情况下在 HIV-1 感染者中的安全性和免疫原性。
J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26.
4
Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.基于改良安卡拉痘苗病毒的 HIV 候选疫苗的临床前研究:抗原呈递和抗病毒作用。
J Virol. 2010 May;84(10):5314-28. doi: 10.1128/JVI.02329-09. Epub 2010 Mar 10.
5
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.针对C亚型HIV-1包膜糖蛋白/ gag - Pol - Nef抗原的新型HIV/AIDS候选疫苗的产生及免疫原性
Vaccine. 2007 Mar 1;25(11):1969-92. doi: 10.1016/j.vaccine.2006.11.051. Epub 2006 Dec 6.
6
Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.通过删除阻断干扰素信号通路的痘苗病毒基因(C6L和K7R)来改善HIV/AIDS候选疫苗MVA-B的适应性免疫和记忆免疫反应
PLoS One. 2013 Jun 27;8(6):e66894. doi: 10.1371/journal.pone.0066894. Print 2013.
7
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.基于减毒痘病毒株MVA和NYVAC在单个位点共表达HIV-1 BX08 gp120和B亚型HIV-1(IIIB)Gag-Pol-Nef蛋白的两种HIV/AIDS候选疫苗免疫原性的直接比较。
Vaccine. 2007 Apr 12;25(15):2863-85. doi: 10.1016/j.vaccine.2006.09.090. Epub 2006 Oct 16.
8
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.在 HIV/AIDS 候选疫苗 MVA-C 中删除病毒抗凋亡基因 F1L 可增强针对 HIV-1 抗原的免疫应答。
PLoS One. 2012;7(10):e48524. doi: 10.1371/journal.pone.0048524. Epub 2012 Oct 31.
9
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.候选艾滋病毒/艾滋病疫苗(MVA-B)缺乏牛痘病毒基因 C6L 可增强记忆 HIV-1 特异性 T 细胞应答。
PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.
10
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.减毒痘病毒载体MVA和NYVAC感染未成熟人单核细胞衍生树突状细胞后的独特基因表达谱。
J Virol. 2007 Aug;81(16):8707-21. doi: 10.1128/JVI.00444-07. Epub 2007 May 30.

引用本文的文献

1
Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus.从感染和重组牛痘病毒的vero 细胞中同时感染和超感染的改良安卡拉痘苗病毒载体流感疫苗和天然牛痘病毒获得的重组病毒的全基因组测序。
Front Immunol. 2024 Apr 3;15:1277447. doi: 10.3389/fimmu.2024.1277447. eCollection 2024.
2
An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses.基于 MVA 的载体表达无细胞 ISG15 可增加 IFN-I 的产生并改善 HIV-1 特异性 CD8 T 细胞免疫应答。
Front Cell Infect Microbiol. 2023 May 29;13:1187193. doi: 10.3389/fcimb.2023.1187193. eCollection 2023.
3
Expression of HSPA14 in patients with acute HIV-1 infection and its effect on HIV-1 replication.在急性 HIV-1 感染患者中 HSPA14 的表达及其对 HIV-1 复制的影响。
Front Immunol. 2023 Feb 9;14:1123600. doi: 10.3389/fimmu.2023.1123600. eCollection 2023.
4
Multi-omics profiling identifies C1QA/B macrophages with multiple immune checkpoints associated with esophageal squamous cell carcinoma (ESCC) liver metastasis.多组学分析鉴定出具有多个与食管鳞状细胞癌(ESCC)肝转移相关免疫检查点的C1QA/B巨噬细胞。
Ann Transl Med. 2022 Nov;10(22):1249. doi: 10.21037/atm-22-5351.
5
Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications.基于安卡拉改良痘苗病毒疫苗的研发:优势与应用
Vaccines (Basel). 2022 Sep 13;10(9):1516. doi: 10.3390/vaccines10091516.
6
Extracellular Vesicles and Their Use as Vehicles of Immunogens.细胞外囊泡及其作为免疫原载体的用途。
Methods Mol Biol. 2022;2504:177-198. doi: 10.1007/978-1-0716-2341-1_13.
7
Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B.删除痘苗病毒A40R基因可提高HIV-1候选疫苗MVA-B的免疫原性。
Vaccines (Basel). 2020 Feb 6;8(1):70. doi: 10.3390/vaccines8010070.
8
V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.HIV-1疫苗研究与自然感染中的V2特异性抗体:控制因素还是替代标志物
Vaccines (Basel). 2019 Aug 6;7(3):82. doi: 10.3390/vaccines7030082.
9
Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?安卡拉痘苗病毒载体的危害特征:有哪些知识空白?
Viruses. 2017 Oct 29;9(11):318. doi: 10.3390/v9110318.
10
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.病毒样颗粒作为一种预防 HIV 感染的疫苗接种方法的最新进展。
Vaccines (Basel). 2016 Jan 22;4(1):2. doi: 10.3390/vaccines4010002.

本文引用的文献

1
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
2
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.改良安卡拉痘苗病毒(MVA)的天然免疫传感由TLR2-TLR6、MDA-5和NALP3炎性小体介导。
PLoS Pathog. 2009 Jun;5(6):e1000480. doi: 10.1371/journal.ppat.1000480. Epub 2009 Jun 19.
3
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.重组改良安卡拉痘苗病毒(MVA)尽管存在预先存在的痘苗免疫力,但仍能有效增强人体中DNA启动的HIV特异性免疫反应。
Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29.
4
Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy.1型人类免疫缺陷病毒的gp120对CD4 + T细胞迁移的重编程为淋巴结病提供了一种机制。
J Virol. 2009 Jun;83(11):5765-72. doi: 10.1128/JVI.00130-09. Epub 2009 Mar 18.
5
Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression.改良安卡拉痘病毒通过诱导CCL2表达触发单核细胞的趋化作用和白细胞的早期呼吸道迁移。
J Virol. 2009 Mar;83(6):2540-52. doi: 10.1128/JVI.01884-08. Epub 2009 Jan 7.
6
Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.Toll样受体诱导NKG2D配体MICA表达后单核细胞与自然杀伤细胞的相互作用
J Immunol. 2008 Nov 15;181(10):6711-9. doi: 10.4049/jimmunol.181.10.6711.
7
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.用异源HIV-1重组改良安卡拉痘苗病毒加强免疫的多基因、多分支HIV-1 DNA疫苗具有广泛的免疫原性。
J Infect Dis. 2008 Nov 15;198(10):1482-90. doi: 10.1086/592507.
8
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.安卡拉痘苗病毒修饰株在血液淋巴细胞中优先靶向树突状细胞,并在体内诱导病毒特异性T细胞反应中起关键作用。
BMC Immunol. 2008 Apr 15;9:15. doi: 10.1186/1471-2172-9-15.
9
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.痘病毒载体MVA和NYVAC作为用于预防传染病和癌症疫苗接种的基因递送系统。
Curr Gene Ther. 2008 Apr;8(2):97-120. doi: 10.2174/156652308784049363.
10
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.用NYVAC和MVA载体疫苗进行气溶胶免疫是安全、简便且具有免疫原性的。
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2046-51. doi: 10.1073/pnas.0705191105. Epub 2008 Feb 11.

MVA-B 对宿主基因的选择性诱导,一种针对 HIV/AIDS 的候选疫苗。

Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

机构信息

Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología CSIC, Campus Universidad Autónoma, E-28049 Madrid, Spain.

出版信息

J Virol. 2010 Aug;84(16):8141-52. doi: 10.1128/JVI.00749-10. Epub 2010 Jun 9.

DOI:10.1128/JVI.00749-10
PMID:20534857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2916545/
Abstract

The aim of this study was to define the effects on antigen-presenting cells of the expression of HIV antigens from an attenuated poxvirus vector. We have analyzed the transcriptional changes in gene expression following infection of human immature monocyte-derived dendritic cells (DC) with recombinant modified vaccinia virus Ankara (MVA) expressing the genes encoding the gp120 and Gag-Pol-Nef antigens of HIV type 1 clade B (referred to as MVA-B) versus parental MVA infection. Using microarray technology and real-time reverse transcription-PCR, we demonstrated that the HIV proteins induced the expression of cytokines, cytokine receptors, chemokines, chemokine receptors, and molecules involved in antigen uptake and processing, including major histocompatibility complex (MHC) genes. Levels of mRNAs for interleukin-1, beta interferon, CCR8, and SCYA20 were higher after HIV antigen production. MVA-B infection also modulated the expression of antigen processing and presentation genes: the gene for MICA was upregulated, whereas those for HLA-DRA and HSPA5 were downregulated. Indeed, the increased expression of the gene for MICA, a glycoprotein related to major histocompatibility complex class I molecules, was shown to enhance the interaction between MVA-B-infected target cells and cytotoxic lymphocytes. The expression profiles of the genes for protein kinases such as JAK1 and IRAK2 were activated after HIV antigen expression. Several genes included in the JAK-STAT and mitogen-activated protein kinase signaling pathways were regulated after HIV antigen expression. Our findings provide the first gene signatures in DC of a candidate MVA-B vaccine expressing four HIV antigens and identified the biological roles of some of the regulatory genes, like that for MICA, which will help in the design of more effective MVA-derived vaccines.

摘要

本研究旨在确定表达减毒痘病毒载体 HIV 抗原对抗原呈递细胞的影响。我们分析了人未成熟单核细胞来源树突状细胞(DC)感染重组改良安卡拉痘苗病毒(MVA)后基因表达的转录变化,该病毒表达 HIV-1 型 B 群的 gp120 和 gag-pol-nef 基因(称为 MVA-B)与亲本 MVA 感染相比。使用微阵列技术和实时逆转录-PCR,我们证明 HIV 蛋白诱导细胞因子、细胞因子受体、趋化因子、趋化因子受体和参与抗原摄取和加工的分子(包括主要组织相容性复合体(MHC)基因)的表达。HIV 抗原产生后,白细胞介素-1、β干扰素、CCR8 和 SCYA20 的 mRNA 水平更高。MVA-B 感染还调节了抗原加工和呈递基因的表达:MICA 基因上调,而 HLA-DRA 和 HSPA5 基因下调。事实上,与主要组织相容性复合体 I 分子相关的糖蛋白 MICA 基因的表达增加,增强了 MVA-B 感染靶细胞与细胞毒性淋巴细胞之间的相互作用。表达蛋白激酶(如 JAK1 和 IRAK2)的基因表达谱在 HIV 抗原表达后被激活。在 HIV 抗原表达后,JAK-STAT 和丝裂原活化蛋白激酶信号通路中的几个基因被调控。我们的研究结果提供了表达四个 HIV 抗原的候选 MVA-B 疫苗在 DC 中的第一个基因特征,并确定了一些调节基因(如 MICA 基因)的生物学作用,这将有助于设计更有效的基于 MVA 的疫苗。